

Hanny Al-Samkari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/562452/publications.pdf>

Version: 2024-02-01

120
papers

3,865
citations

186265
28
h-index

144013
57
g-index

120
all docs

120
docs citations

120
times ranked

5234
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. <i>Platelets</i> , 2022, 33, 66-72.	2.3	18
2	Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. <i>Platelets</i> , 2022, 33, 257-264.	2.3	21
3	Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. <i>Angiogenesis</i> , 2022, 25, 87-97.	7.2	20
4	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. <i>Blood Advances</i> , 2022, 6, 1844-1853.	5.2	12
5	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. <i>Blood</i> , 2022, 139, 1564-1574.	1.4	55
6	Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. <i>Neuro-Oncology</i> , 2022, 24, 964-973.	1.2	6
7	Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 708-711.	2.1	3
8	Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia. <i>Drugs of Today</i> , 2022, 58, 105-116.	1.1	1
9	Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. <i>British Journal of Haematology</i> , 2022, 197, 359-366.	2.5	31
10	Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 514-528.	2.7	11
11	Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e179-e189.	4.6	23
12	A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1077-1088.	3.8	16
13	Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29447.	1.5	6
14	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. <i>New England Journal of Medicine</i> , 2022, 386, 1432-1442.	27.0	42
15	Doxycycline for bleeding in hereditary hemorrhagic telangiectasia: When low-changing fruit meets inconvenient data. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1067-1069.	3.8	0
16	The case for classical haematology: the impact of a name and the future of a field. <i>Lancet Haematology</i> , 2022, 9, e455-e459.	4.6	3
17	Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. <i>Cancer</i> , 2022, 128, 3224-3232.	4.1	12
18	An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 783-791.	3.0	4

#	ARTICLE	IF	CITATIONS
19	Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 255-259.	2.1	5
20	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. <i>Haematologica</i> , 2021, 106, 2161-2169.	3.5	64
21	The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. <i>British Journal of Haematology</i> , 2021, 192, 1092-1096.	2.5	15
22	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. <i>Haematologica</i> , 2021, 106, 1148-1157.	3.5	49
23	An Eltrombopag Red (Plasma) Alert. <i>Acta Haematologica</i> , 2021, 144, 227-228.	1.4	2
24	Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. <i>Blood</i> , 2021, 137, 888-895.	1.4	45
25	New therapeutic horizons in Wiskott-Aldrich syndrome. <i>British Journal of Haematology</i> , 2021, 192, 231-232.	2.5	0
26	Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. <i>Haemophilia</i> , 2021, 27, e270-e273.	2.1	2
27	An evaluation of avatrombopag for the treatment of thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 273-280.	1.8	19
28	Comorbidities and complications in adults with pyruvate kinase deficiency. <i>European Journal of Haematology</i> , 2021, 106, 484-492.	2.2	17
29	d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2021, 49, e500-e511.	0.9	35
30	Recognition of thrombotic risk of thrombocytosis in iron deficiency. <i>Haematologica</i> , 2021, 106, 661-663.	3.5	10
31	Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1613.	7.4	19
32	Tissue Plasminogen Activator in Critically Ill Adults with COVID-19. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1917-1921.	3.2	11
33	Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1852-1863.	3.8	17
34	Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. <i>Expert Review of Hematology</i> , 2021, 14, 437-448.	2.2	29
35	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 622-632.	3.9	89
36	Severe babesiosis with associated splenic infarcts and asplenia. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 597-599.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2348-2354.	3.8	7
38	Giving hereditary haemorrhagic telangiectasia the attention it deserves. <i>Lancet Haematology</i> , the, 2021, 8, e472-e474.	4.6	5
39	Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 653-664.	1.7	25
40	Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. <i>JAMA Network Open</i> , 2021, 4, e2119812.	5.9	9
41	Response to rituximab in children and adults with immune thrombocytopenia (ITP). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12587.	2.3	4
42	Recognition and management of vascular lesions in von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2122-2124.	3.8	0
43	Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome. <i>Blood Advances</i> , 2021, 5, 3850-3854.	5.2	9
44	Severe autoimmune hemolytic anemia following receipt of <scp>SARSâ€CoV</scp>â€2 <scp>mRNA</scp> vaccine. <i>Transfusion</i> , 2021, 61, 3267-3271.	1.6	29
45	Predictors of mortality and outcomes of liver transplant in spur cell hemolytic anemia. <i>American Journal of Hematology</i> , 2021, 96, 1611-1620.	4.1	4
46	Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report. <i>Annals of Internal Medicine</i> , 2021, 174, 1632-1633.	3.9	8
47	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapyâ€induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, 1563-1568.	4.1	6
48	TPO versus TPO: the good, the bad, and the to be determined. <i>British Journal of Haematology</i> , 2021, 195, 653-654.	2.5	0
49	Hospitalization As a Risk Factor for Bleeding: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study. <i>Blood</i> , 2021, 138, 1915-1915.	1.4	0
50	Venous and Arterial Thrombosis Following Abemaciclib Therapy for Metastatic Breast Cancer. <i>Blood</i> , 2021, 138, 4063-4063.	1.4	2
51	Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia. <i>Blood</i> , 2021, 138, 584-584.	1.4	0
52	Predictors of Mortality and Outcomes of Liver Transplant in Spur Cell Hemolytic Anemia. <i>Blood</i> , 2021, 138, 1995-1995.	1.4	0
53	Characterization and Prognosis of Temozolomide-Induced Aplastic Anemia. <i>Blood</i> , 2021, 138, 2193-2193.	1.4	1
54	Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study. <i>Blood</i> , 2021, 138, 1015-1015.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood, 2021, 138, 586-586.	1.4	1
56	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848.	1.4	1
57	Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias. Therapeutic Advances in Hematology, 2021, 12, 204062072110660.	2.5	31
58	Platelet clump visible to the naked eye in type 2B von Willebrand disease. Blood, 2021, 138, 2742-2742.	1.4	0
59	Cancer-associated thrombosis: Where do we stand?. Advances in Cell and Gene Therapy, 2020, 3, e73.	0.9	4
60	The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. European Journal of Haematology, 2020, 104, 79-87.	2.2	112
61	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. Seminars in Thrombosis and Hemostasis, 2020, 46, 275-288.	2.7	49
62	Striving for full disclosure—An intergenerational challenge. Cancer, 2020, 126, 1150-1151.	4.1	10
63	Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 807-812.	2.3	25
64	Cancer and thrombosis: new insights to an old problem. JMV-Journal De Medecine Vasculaire, 2020, 45, 6S8-6S16.	0.2	22
65	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine, 2020, 173, 989-1001.	3.9	244
66	Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients. Cancers, 2020, 12, 1958.	3.7	21
67	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	4.1	8
68	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (<sc>COVID</sc>19). American Journal of Hematology, 2020, 95, 1479-1485.	4.1	24
69	A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1340-1342.	2.3	5
70	An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Haemophilia, 2020, 26, 1038-1045.	2.1	19
71	The role of romiplostim for pediatric patients with immune thrombocytopenia. Therapeutic Advances in Hematology, 2020, 11, 204062072091299.	2.5	19
72	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020, 136, 489-500.	1.4	1,021

#	ARTICLE	IF	CITATIONS
73	How to focus our efforts in improving prognostic disclosure in oncology. <i>Cancer</i> , 2020, 126, 2716-2717.	4.1	3
74	ABO phenotype and death in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e204-e208.	2.5	62
75	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. <i>American Journal of Hematology</i> , 2020, 95, 1180-1186.	4.1	26
76	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00118.	2.5	3
77	Partial Suture Fusion in Nonsyndromic Single-Suture Craniosynostosis. <i>Cleft Palate-Craniofacial Journal</i> , 2020, 57, 499-505.	0.9	3
78	The variable manifestations of disease in pyruvate kinase deficiency and their management. <i>Haematologica</i> , 2020, 105, 2229-2239.	3.5	30
79	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 9-18.	5.2	56
80	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506.	1.1	46
81	Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. <i>Drugs of Today</i> , 2020, 56, 439.	1.1	10
82	Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature. <i>Blood</i> , 2020, 136, 45-46.	1.4	1
83	Characteristics of Children and Adults Treated with Rituximab for Immune Thrombocytopenia (ITP). <i>Blood</i> , 2020, 136, 38-39.	1.4	0
84	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2020, 136, 30-32.	1.4	3
85	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020, 136, 14-14.	1.4	0
86	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020, 136, 4-5.	1.4	0
87	<p>Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 175-186.	2.3	19
88	Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 256.	2.7	25
89	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. <i>British Journal of Haematology</i> , 2019, 187, e61-e64.	2.5	6
90	<p>Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease</p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 313-321.	1.7	38

#	ARTICLE	IF	CITATIONS
91	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Therapeutic Advances in Hematology, 2019, 10, 204062071984173.	2.5	65
92	Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Chest, 2019, 155, 1226-1233.	0.8	14
93	Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies. Otolaryngology - Head and Neck Surgery, 2019, 160, 368-368.	1.9	12
94	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. Annals of Internal Medicine, 2019, 170, 904.	3.9	9
95	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Advances, 2019, 3, 3770-3779.	5.2	58
96	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. Blood Advances, 2019, 3, 3515-3521.	5.2	24
97	Thrombophilia evaluation in pulmonary embolism. Current Opinion in Cardiology, 2019, 34, 603-609.	1.8	9
98	Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. Journal of Internal Medicine, 2019, 285, 223-231.	6.0	48
99	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Annals of Hematology, 2019, 98, 581-588.	1.8	34
100	Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. British Journal of Anaesthesia, 2019, 122, 19-31.	3.4	73
101	Optimal anticoagulant treatment of cancer-associated venous thromboembolism remains unclear. BMJ Evidence-Based Medicine, 2019, 24, 115-116.	3.5	1
102	Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the <i>PRF1A91V</i> gene polymorphism. Journal of Medical Genetics, 2019, 56, 39-42.	3.2	25
103	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Hematology American Society of Hematology Education Program, 2019, 2019, 71-79.	2.5	9
104	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. Blood, 2019, 134, 1060-1060.	1.4	0
105	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	1.4	0
106	Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. American Journal of Hematology, 2018, 93, E156-E158.	4.1	8
107	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica, 2018, 103, e169-e172.	3.5	51
108	Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Thrombolysis, 2018, 46, 81-83.	2.1	13

#	ARTICLE	IF	CITATIONS
109	Hemophagocytic Lymphohistiocytosis. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 27-49.	22.4	299
110	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. Haematologica, 2018, 103, e492-e495.	3.5	6
111	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. American Journal of Hematology, 2018, 93, 1501-1508.	4.1	55
112	Romiplostim for the management of perioperative thrombocytopenia. British Journal of Haematology, 2018, 182, 106-113.	2.5	37
113	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica, 2018, 103, 1433-1443.	3.5	123
114	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. British Journal of Haematology, 2018, 183, 168-168.	2.5	26
115	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. British Journal of Clinical Pharmacology, 2018, 84, 2673-2677.	2.4	24
116	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. Cancers, 2018, 10, 271.	3.7	33
117	Shifting landscape of hemophilia therapy: Implications for current clinical laboratory coagulation assays. American Journal of Hematology, 2018, 93, 1082-1090.	4.1	19
118	Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease. Drugs of Today, 2018, 54, 647.	1.1	13
119	Anticoagulation and Enzalutamide: Caution Over Convenience. Journal of Oncology Practice, 2017, 13, 728-729.	2.5	4
120	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. Blood, 2016, 128, 3748-3748.	1.4	2